investor.alkermes.comInvestors | Alkermes plc
investor.alkermes.com Profile
Investor.alkermes.com is a subdomain of alkermes.com, which was created on 1995-10-03,making it 29 years ago.
Description：The Investor Relations website contains information about Alkermes plc's business for stockholders, potential investors, and financial...
Discover investor.alkermes.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investor.alkermes.com Information
| HomePage size: 67.616 KB |
| Page Load Time: 0.735638 Seconds |
| Website IP Address: 23.47.145.25 |
investor.alkermes.com Similar Website
| Aptiv PLC - Investor Information |
| Pentair plc Investor Relations |
| Maryland Real Estate Investors Association - Maryland Real Estate Investors Association |
| nVent Electric plc - Investor Relations |
| Home - Vitafoam Nigeria Plc |
| Welcome (Expert LR7.2) - Hays PLC |
| Western Midstream - Investors - Investors |
| OMNOVA Solutions - Investors - Investors |
| Investors | Marathon Oil Corporation - Investors |
| Axalta Coating Systems - Investors - Investors Overview |
| Investors | Horizon Therapeutics plc |
| Investors | ICON plc |
| Connected Investors | Connect With Real Estate Investors |
| Investors - TechnipFMC plc |
| Investors - Toromont Industries Ltd. - Investors |
investor.alkermes.com PopUrls
| Investors | Alkermes plc https://investor.alkermes.com/ |
| Compensation - Investors | Alkermes plc https://investor.alkermes.com/committee-details/compensation/ |
| 0000950170-24-042791 | 8-K | XBRL Viewer | Alkermes PLC https://investor.alkermes.com/node/21506/xbrl-viewer |
| 0000950170-23-034556 | 8-K | iXBRL Viewer | Alkermes PLC https://investor.alkermes.com/node/20916/ixbrl-viewer |
investor.alkermes.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1621220435" |
| Expect-CT: max-age=0, report-uri="/report-expect-ct-violation" |
| Feature-Policy: "accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr none", From-Origin: same |
| Last-Modified: Mon, 17 May 2021 03:00:35 GMT |
| Link: http://investor.alkermes.com/; rel="shortlink", https://investor.alkermes.com/investor-relations/; rel="canonical", https://investor.alkermes.com/investor-relations; rel="alternate"; hreflang="en", https://investor.alkermes.com/investor-relations; rel="revision" |
| Referrer-Policy: no-referrer-when-downgrade |
| X-Age: 0 |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Request-ID: v-0ce55396-b6bc-11eb-aa21-b7a8458bd52c |
| X-UA-Compatible: IE=edge |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 13454 |
| Cache-Control: public, max-age=0, s-maxage=2700 |
| Expires: Mon, 17 May 2021 03:00:35 GMT |
| Date: Mon, 17 May 2021 03:00:35 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/; Secure; HttpOnly |
| Strict-Transport-Security: max-age=15768000 ; preload |
investor.alkermes.com Meta Info
| charset="utf-8"/ |
| content="Alkermes plc" property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about Alkermes plc's business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="https://investor.alkermes.com/investor-relations" property="og:url"/ |
| content="Investors | Alkermes plc" property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about Alkermes plc's business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
investor.alkermes.com Ip Information
| Ip Country: United States |
| City Name: Secaucus |
| Latitude: 40.7876 |
| Longitude: -74.06 |
investor.alkermes.com Html To Plain Text
Discover Alkermes Our Values Leadership Diversity, Inclusion & Belonging Partnering Locations Medicines & Focus Our Focus Disease Areas Innovative Medicines Third Party Medicines Research & Development Pipeline Scientific Platforms Technologies & Capabilities Research & Medical Grants Clinical Trials Early Access Responsibility Corporate Responsibility Patient Engagement & Advocacy Alkermes Inspiration Grants® Corporate Giving Corporate Responsibility Reports Public Policy Investors Press Releases Investor Events / Presentations SEC Filings Annual Reports Corporate Governance Stock Information Investor Resources Email Alerts News & Events Press Releases Company Events Media Resources Statements Contact Us Careers Working Here Our Culture Benefits Join Our Team Investors Corporate Profile Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. Press Releases 05/13/21 Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer 05/05/21 Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference 05/03/21 Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month Site - View All - News Read more Investor Events 05/12/21 at 2:45 PM EDT BofA Securities 2021 Virtual Healthcare Conference 04/28/21 at 8:00 AM EDT Q1 2021 Alkermes plc Earnings Conference Call 04/01/21 at 8:30 AM EDT Stifel’s 3rd Annual CNS Day Site - View All - Events Read more Quarterly Results Show all 2021 2020 Q1 2021 Earnings Release 10-Q Webcast Presentation 546.2 KB Q4 2020 Earnings Release 10-K Webcast Presentation 598.7 KB Q3 2020 Earnings Release 10-Q Webcast Presentation 462.2 KB Q2 2020 Earnings Release 10-Q Webcast Presentation 483.4 KB Q1 2020 Earnings Release 10-Q Presentation 619.9 KB Stock Quote Exchange Price Change Volume Refresh quote Data as of 05/16/21 11:00 PM EDT Minimum 15 minutes delayed. Data Provided by Refinitiv. Stock Chart Email Alerts Submit Investor Tools Print Page Contact Us RSS Email Alerts Contact Us Terms of Use Privacy Policy Sitemap ©2021 Alkermes . All Rights...
investor.alkermes.com Whois
Domain Name: ALKERMES.COM Registry Domain ID: 5361793_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2023-10-02T04:24:37Z Creation Date: 1995-10-03T04:00:00Z Registry Expiry Date: 2033-10-02T04:00:00Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: domain.operations@web.com Registrar Abuse Contact Phone: +1.8777228662 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS59.WORLDNIC.COM Name Server: NS60.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T21:44:43Z <<<